1ST ANNUAL

EGFR Resisters RESEARCH SUMMIT

November 15–16, 2019
Omni Chicago Hotel
Chicago, Illinois
www.egfrsummit.com

NEWSLETTER

EGFR RESISTERS RESEARCH SUMMIT OVERVIEW

The *Inaugural EGFR Resisters Research Summit* convened on Friday, November 15, 2019, at the Omni Hotel in Chicago, IL.

Sixteen Young Investigators and seven Expert Faculty Judge Mentors kicked off the meeting with a professional development & mentoring panel focused on real-world topics impacting early career researchers, including finding mentors, writing grants, and working with cooperative groups. During the Friday reception, founding members of the EGFR Resisters, Ivy Elkins, Jill Feldman, and Dr. Ildiko Medve, formally set the tone for the inaugural EGFR Resisters Research Summit. Each of the three patients presented slides delineating the mission of the *EGFR Resisters* and the critical need for research advancements in *EGFR*m non-small cell lung cancer; prominent recent breakthroughs were discussed, as were significant obstacles, most notably the relative paucity of funding in the lung cancer therapeutic space. The presentation concluded with a video clip from *The Today Show*, which showcased Jill Feldman's personal journey with lung cancer and ushered EGFR into the national spotlight. An interactive Q&A session with Expert Faculty Judge Mentors and Young Investigators brought the Welcome Reception to a close—and fittingly illustrated the overarching purpose of the EGFR Summit:

To advance the EGFRm treatment paradigm through meaningful collaboration between physician scientist investigators and patients.

Saturday morning began with research presentations by Clinical Fellows, followed by a Meet-the-Professor mentorship lunch where Young Investigators were invited to sit with one of the Judge Mentors in a more intimate setting. Junior Faculty presented their research during the afternoon session, and the day concluded with an Awards Dinner, where six Young Investigators were honored for their exemplary work— the EGFR Resisters Distinguished Young Investigator Grand Prize, 1st Runner-Up, 2nd Runner-Up, and three Honorable Mentions.

ABOUT THE EGFR RESISTERS PATIENT ADVOCACY GROUP

Founded in 2018 by seven original members, the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing *EGFR* mutated lung cancer into a chronic, manageable disease. With more than 1,900 members from 75 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project Priority and the recently-inaugurated EGFR Resisters Research Summit, a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers.

CEC Oncology is excited and honored to partner with the EGFR Resisters in organizing and delivering the Summit on an annual basis.

cec oncology

EGFR resisters

2019 EGFR RESISTERS DISTINGUISHED YOUNG INVESTIGATOR GRAND PRIZE—$10,000

Jake June-Koo Lee, MD, PhD
Postdoctoral Fellow
Harvard Medical School

Mutational History of EGFR-mutant Lung Adenocarcinoma

"This research summit was my first EGFR-mutation–focused research meeting in which I could meet the experts of this field, budding young investigators, as well as patient advocates. This meeting provided me a valuable opportunity to share my findings on genomic alterations in EGFR-mutant lung adenocarcinomas and to better understand the perspectives of patients."

"[The award will be used toward] purchase of computational appliances, books and office articles, and travel expenses for academic meetings."

1ST RUNNER-UP—$1,500

Brian S. Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University

Leveraging Network-based Inference of Protein Activity in EGFR-mutant Lung Adenocarcinoma (LUAD) Predicts Primary Tyrosine Kinase Inhibitor (TKI) Resistance

"I am extremely grateful to the organizers for the opportunity to participate in the Research Summit. Meeting and interacting with other investigators studying EGFR-mutant lung cancer was a valuable early-career experience but, most inspiringly, this was a chance to meet and hear from patients whose lives and well-being depend on continued progress. This kind of exposure gives a more complete picture to the field I hope to contribute to that extends beyond what can occur within one's home institution."

"The next steps for the work I presented at the retreat include collection of patient samples for prospective analysis. I plan to use the award money toward these efforts."

2ND RUNNER-UP—$1,000

Adam Schoenfeld, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center

Paired Tumor Tissue Analyses Reveals Squamous Transformation as a Common Early Arising Mechanism of Resistance to Osimertinib in EGFR-mutant Lung Cancers

"During my career as an academic medical oncologist, I will focus on improving treatments for people with lung cancer by conducting innovative early phase clinical trials and translational research. Attending the Research Summit enabled me to share my recent work identifying new mechanisms of resistance to osimertinib in EGFR-mutant lung cancer and build relationships for future translational collaborations."

"[The award will be used] for presentation of research at nationwide conferences."

HONORABLE MENTIONS—$750

Christine M. Bestvina, MD
Assistant Professor
University of Chicago

Epigenomic Mapping of Cell-free DNA in Patients with EGFR-mutated Non–Small Cell Lung Cancer

"The Research Summit was an excellent opportunity to network and to discuss other potential research collaborations. I have since had a phone conversation with Dr. Christine Lovly and my basic science collaborator, Chuan He, to discuss additional research applications for our technology."

"I plan to use my grant award to fund additional processing of samples to perform epigenomic mapping of cell-free DNA."

Joshua Sabari, MD
Assistant Professor of Medicine
Thoracic Medical Oncology
NYU School of Medicine

JNJ-61186372 (JNJ-372), an EGFR-cMet Bispecific Antibody, in EGFR-driven Advanced Non–Small Cell Lung Cancer (NSCLC): Tumor Heterogeneity and Response to Therapy

"The EGFR Research Summit was a great opportunity to meet leaders in the field, patient advocates, and colleagues inter-ested in the study and development of better treatment options for patients with EGFR-mutant lung cancer. It gave me new ideas and allowed me to forge new collaborations in the field."

"I will use this grant funding as startup funds for our EGFR resistance mechanism project."

Takeshi Shimamura, PhD, MS
Visiting Associate Professor
University of Illinois–Chicago

MIF Stimulates CXCR7 to Activate ERK Signaling to Promote Resistance to EGFR TKI Inhibitors in NSCLC

"The meeting enabled me to connect with scientists who study NSCLC with EGFR mutations. We, as a group of scientists with similar interests, can streamline the discovery process by collaborating with each other."

"We will use the grant award to print posters for upcoming scientific meetings, including AACR and IASLC. The award will also be used to help defray the cost of publishing our manuscripts. We will give credit to the award from the EGFR Resisters."

2019 EGFR RESISTERS RESEARCH SUMMIT ATTENDEES

Jacqueline V. Aredo, BS
Medical Student Research Assistant
Stanford University
Osimertinib in Patients with Atypical EGFR Mutations in Non–Small Cell Lung Cancer: A Retrospective Series

Christine M. Bestvina, MD
Assistant Professor
University of Chicago
Epigenomic Mapping of Cell-free DNA in Patients with EGFR-mutated Non–Small Cell Lung Cancer

Gabriela Bravo Montenegro, MD
Hematology/Oncology Fellow
Georgetown University
Spectrum of EGFR Exon 20 Insertion Mutations and Co-occurring Genetic Alterations in Patients with Non–Small Cell Lung Cancer

Oliver S. Chow, MD
Assistant Professor of Clinical Cardiothoracic Surgery
Weill Cornell Medicine, NY Presbyterian
Superior Survival in Early Stage Lung Adenocarcinoma Patients with EGFR Mutations: Stopping Resistance before It Starts

Brendan Gilmore, MD
Hematology/Oncology Fellow
Rush University Medical Center
Neutrophil-to-Lymphocyte Ratio as an Early Marker of Outcomes in Patients with Epidermal Growth Factor Receptor Mutation Positive Advanced Non–Small-Cell Lung Cancer

Nicholas Peter Giustini, MD
Hematology/Oncology Fellow
University of California, San Diego
Case Series and Review of the Literature Illustrating Resistance to EGFR TKI through the Development of Secondary Oncogenic Drivers

Brian S. Henick, MD
Assistant Professor of Medicine at CUIMC
Columbia University
Leveraging Network-based Inference of Protein Activity in EGFR-mutant Lung Adenocarcinoma (LUAD) Predicts Primary Tyrosine Kinase Inhibitor (TKI) Resistance

Maya Khalil, MD
Hematology-Oncology Fellow
Roswell Park Comprehensive Cancer Center
The Tumor Immune Microenvironment in EGFR-driven Loco-regional Lung Adenocarcinoma Can Predict Higher Risk of Recurrence

Xiuning Le, MD, PhD
Assistant Professor
MD Anderson Cancer Center
Characterization of the Tumor-Immune Microenvironment in Treatment-naïve EGFR-mutant NSCLC Uncovers CD73/Adenosine Pathway-related T Cell Dysfunction

Jake June-Koo Lee, MD, PhD
Postdoctoral Fellow
Harvard Medical School
Mutational History of EGFR-mutant Lung Adenocarcinoma

Jia Luo, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
ctDNA Guided EGFR Inhibition as Adjuvant Therapy for EGFR Mutation Positive NSCLC

Nicolas Marcoux, MD, FRCPC
Hematologist/Oncologist
CHU de Quebec
Real-world cfDNA Collection in EGFR-mutant NSCLC

Joshua Sabari, MD
Assistant Professor of Medicine at CUIMC
Columbia University
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific Antibody, in EGFR-driven Advanced Non-Small Cell Lung Cancer (NSCLC): Tumor Heterogeneity and Response to Therapy

Adam Schoenfeld, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
Paired Tumor Tissue Analyses Reveals Squamous Transformation as a Common Early Arising Mechanism of Resistance to Osimertinib in EGFR-mutant Lung Cancers

Takeshi Shimamura, PhD, MS
Visiting Associate Professor
University of Illinois–Chicago
MIF Stimulates CXCR7 to Activate ERK Signaling to Promote Resistance to EGFR TKI Inhibitors in NSCLC

Li Zheng, PhD
Research Associate Professor
City of Hope Beckman Research Institute
HSP72 Expression Associates with Survival in EGFR-mutated NSCLC

2019 EGFR RESISTERS RESEARCH SUMMIT EDUCATIONAL HIGHLIGHTS



Professional Skills Enhancement Workshop

In an effort to augment the professional development aspects of this program, CEC brought in our team of professional coaching experts from *ListenWritePresent* who have a long history of working with prospective and existing faculty in the medical and scientific space. Their team provided one-on-one coaching opportunities for each Young Investigator presenter on Friday prior to the launch of the meeting with sessions that included: presentation rehearsal, individualized coaching feedback on visual and verbal skills using video recording, and receipt of a personalized "Skill Builder" presentation at the end of the session.

2019 EGFR Resisters Research Summit attendees found the ***ListenWritePresent* Professional Skills Enhancement Workshop** to be an extremely valuable component of the EGFR Summit curriculum, ranking the coaching sessions with a mean score of **3.82** on a 4.0 scale.

2019 EGFR RESISTERS RESEARCH SUMMIT ON SOCIAL MEDIA @EGFRSummit

EGFR Resisters Research Summit @EGFRSummit · Nov 16, 2019
Dr @christine_lovly on #EGFRSummit19: "Most importantly, this Summit is about partnering with patients to advance research in this field...it takes a village to achieve new advances in cancer therapy, and none of us can do this alone." #LCSM @VUMedicine @VUMC_Cancer

EGFR Resisters Research Summit Retweeted

Zosia Piotrowska @ZPiotrowskaMD · Nov 17, 2019
THANK YOU @EGFRResisters @jillfeldman4 @ivybelkins @Medvelldiko and @CEC_Onc for bringing us together for a truly inspiring event! Amazing to meet the next wave of EGFR researchers and hear about the innovative things they are working on. The future is bright! #lcsm #EGFRSummit19

> **Jill** @jillfeldman4 · Nov 16, 2019
> Thank you @EGFRResisters Research Summit judges. Such an honor to work with these smart, passionate and dedicated oncologists! #EGFRSummit19 #LCSM #LCAM @LeciaSequist @HelenaYu923 @ZPiotrowskaMD @christine_lovly @maryjofidlerMD @ivybelkins @Medvelldiko twitter.com/EGFRSummit/sta...

EGFR Resisters Research Summit Retweeted

Lecia Sequist, MD, MPH @LeciaSequist · Nov 15, 2019
@EGFRResisters @jillfeldman4 @ivybelkins @Medvelldiko teaching our young investigators how patient-driven research gives powerful insights into real world experiences that can't be learned in other ways. This is critical to setting research priorities for tomorrow! @EGFRSummit

Maya K. Khalil, MD @MayaKKhalil · Nov 16, 2019
Grateful for the opportunity to meet all of the amazing people organizing #EGFRSummit19, learning from accomplished mentors and making new friends. Such an amazing experience! @EGFRResisters you give meaning to what we do.

> **Joshua Sabari, MD** @JSabari · Nov 16, 2019
> #LCSM @EGFRResisters @EGFRSummit @GabrielaBravoMD @MayaKKhalil @BHenickMD @nickgiustini Inaugural Class 2019

Jill @jillfeldman4 · Nov 16, 2019
Dr. John Heymach of MD Anderson talks to the Fellows and Junior Faculty at the EGFR Research Summit about grant writing. Great advice for new researchers in order to help them get their lung cancer projects funded! #EGFRSummit19 #LCSM #LCAM @EGFRResisters

Jia Luo, MD @Jia_Luo · Nov 17, 2019
Replying to @EGFRSummit @sloan_kettering and @HelenaYu923
Thanks for a fantastic @EGFRSummit @EGFRResisters @ivybelkins @jillfeldman4! Met some great colleagues & faculty and learned a lot. Back in NYC and feeling inspired. #backatit #lcsm



SAVE THE DATE!

2nd Annual EGFR Resisters Research Summit
November 12-14, 2020 •Omni Chicago